Abstract
Background and Aims:
Esophageal strictures are a leading cause of dysphagia, but data regarding the epidemiology of esophageal strictures are limited. This study aimed to investigate the prevalence, healthcare utilization, and financial burden of esophageal strictures in the United States.
Methods:
We performed a retrospective cohort study utilizing two large national insurance claims databases (MarketScan and Medicare). Using ICD-9 and -10 diagnostic codes, annual prevalence was calculated for both cohorts overall, as well as stratified by age and sex strata. Most common diagnostic and procedural codes associated with esophageal strictures were extracted and analyzed to estimate healthcare utilization. Direct annual medical costs of esophageal strictures were calculated.
Results:
The annual prevalence of esophageal strictures in MarketScan in 2021 was 203.14 cases/100,000 people while the annual prevalence in Medicare cohort in 2017 was 1123.47 cases/100,000. While rates were relatively stable over time, esophageal stricture prevalence increased with advancing age. No prevalence differences were noticed between males and females. GERD/erosive esophagitis was the top diagnostic code associated with esophageal strictures, though an increase in the proportion of eosinophilic esophagitis codes was noted over time. Esophageal dilation codes were present in ~50% of stricture cases. The total healthcare costs associated with esophageal strictures were estimated at $1.39 billion in 2017.
Conclusions:
Esophageal strictures are common, affecting between 1/100 to 1/1000 patients in the United States, with the highest rates seen in patients aged 75y and older. Accordingly, strictures have a significant financial burden on the healthcare system, with costs above $1 billion annually.
Keywords: Esophageal stricture, prevalence, eosinophilic esophagitis, erosive esophagitis, costs
Introduction
Esophageal strictures are a major cause of dysphagia and can be subcategorized into benign or malignant based on the underlying etiology.1–4 Peptic strictures secondary to gastroesophageal reflux disease (GERD) are thought to be the most common type, constituting approximately 70–80% of all adult cases.1,2,5–7 Other etiologies of benign strictures include eosinophilic esophagitis (EoE), drug-induced esophagitis, infectious esophagitis, and others, whereas malignant esophageal strictures are due to esophageal cancers.1,2,8–13 Strictures can cause serious consequences without treatment, such as weight loss, pneumonia secondary to aspiration, and esophageal food impaction or, rarely, esophageal perforation.2,4,14 Treatment of esophageal strictures is required to avoid these consequences, and consists of esophageal dilation, and in some refractory cases, stenting, steroid injections, or strictureplasty.4,7,9,15,16
Currently, the esophageal stricture prevalence in the United States is poorly described. Existing estimates of incidence (1.1 per 10,000 person-years) are based on data collected from the United Kingdom (UK) General Practice Research Database between 1994 and 2000,17 and may not be applicable to the U.S. population or to current practice. Furthermore, no studies to date have assessed the financial burden of esophageal strictures on the U.S. healthcare system. Understanding the prevalence in the U.S. could inform the disease burden attributed to esophageal strictures, and potentially inform future guidelines on prevention and treatment.
Therefore, we aimed to estimate the esophageal stricture prevalence in the U.S. and assess treatment utilization and direct medical costs associated with strictures using two large administrative national claim databases.
Materials and Methods
Data Source and Study Design
Two national insurance claims databases were used as the main data source: Merative MarketScan Commercial Claims and Encounters database (age < 65 years) and a 20% random sample of nationwide Medicare Fee-for-Service (Parts A and B) insurance enrollment and claims (age ≥ 65 years). Medicare Advantage plans were not included. Merative MarketScan database is a compiled dataset encompassing de-identified individual patient healthcare data among those with commercial insurance plans, with the data source obtained through employers, states, hospitals, and EMRs.18 In contrast, Medicare beneficiaries include patients in the U.S. who are 65 years or older, those with disabilities, end-stage renal disease, or those suffering from amyotrophic lateral sclerosis (ALS).19 Medicare administrative data encompasses healthcare services utilization data that is collected annually by the Centers for Medicare and Medicaid Services (CMS).20 Using these data sources, we conducted a retrospective cohort study to estimate the prevalence, treatment utilization, and direct medical costs associated with esophageal strictures from 2000 to 2021 (for MarketScan) and from 2007 to 2017 (for Medicare). Our study population comprised patients younger than 65 years old in the MarketScan commercial claims database and patients 65 years or older in the national Medicare enrollment and claims database. We excluded patients 65 years or older in MarketScan as this database only captures a small group of patients with complementary commercial insurance, has missing data in this age group, and we cannot determine which individuals may be reflected in both databases. All analyses were performed using SAS® 9.4.21 This study was deemed to be exempt from ongoing review by the UNC Institutional Review Board.
Prevalence Definitions and Calculations
The annual prevalence of esophageal strictures in the two administrative databases was calculated following a well-established epidemiology methodology proposed by Rassen and colleagues.22,23 Annual prevalence refers to the proportion of enrollees estimated to have an esophageal stricture diagnosis at a specific time point who also had continuous insurance enrollment in the same year of diagnosis over the total number of enrollees with a continuous insurance enrollment in the same lookback window. Prevalent cases of esophageal stricture were defined as the number of enrollees with at least one insurance claim that included an International Classification of Diseases (ICD)-Ninth Revision-Clinical Modification (ICD-9) or ICD-Tenth Revision-Clinical Modification (ICD-10) diagnosis code for esophageal strictures in the lookback window (ICD-9: 530.3; ICD-10: K22.2), in any healthcare setting (inpatient or outpatient) and at any diagnosis position, in a given year. We performed a sensitivity analysis, similar to other published methodology,24 with a secondary definition for esophageal strictures which required the presence of one endoscopic dilation code within one year before or after the esophageal stricture diagnostic code among patients with continuous enrollment. Prevalence was reported as cases/100,000 persons in a given calendar year, and was also calculated separately for males and females and for different age groups in both databases. The age groups in the MarketScan database were set as <18 y, 18–24 y, 25–34 y, 35–44 y, 45–54 y, and 55–64 y. The age groups in the Medicare database included 65–74 y, 75–84 y, and ≥85 y.
Analysis of Diagnostic Codes Associated with Esophageal Strictures
A comprehensive list of possible etiologies of esophageal strictures and their corresponding ICD codes and Current Procedural Terminology (CPT) codes were identified (Supplementary Table 1) as a way of attempting to assess stricture causes in the claims data. The ICD or CPT code associated with an esophageal stricture cause was only included in the analysis when the code occurred within one year before or after the esophageal stricture diagnostic code. These analyses were restricted to stricture cases with continuous insurance enrollment from one year before to one year after stricture diagnosis. Thus, the top diagnostic code analysis did not include the first or last years in the databases, as those years could not capture patients with a one-year continuous enrollment both before and after stricture diagnosis. For Barrett’s Esophagus (BE), we required identified patients with an esophageal stricture diagnosis to both have a BE ICD code within one year before or after the stricture diagnosis and have received an ablation treatment within one year after BE diagnosis, as the presence of uncomplicated BE itself was not felt to be a cause of esophageal strictures, and a single diagnosis code may represent a rule-out code in salmon-colored mucosa without intestinal metaplasia on the biopsies. The proportion of prevalent cases within a given year with a code for that etiology one year before/after stricture diagnosis was then calculated for each identified etiology.
Utilization and Costs
The list of CPT codes related to esophageal strictures treatments is presented in Supplementary Table 2. To measure utilization, we calculated the proportion of prevalent cases within a given year who had a CPT code for that treatment within one year after stricture diagnosis, over the number of prevalent esophageal stricture cases within that year. Only esophageal stricture patients with continuous enrollment during the year after receiving the diagnosis were included for various treatment modalities. The exception was for esophageal dilation where we allowed the code to occur within one year before/after the stricture diagnosis. Additionally, the proportion of esophageal stricture patients with an esophageal perforation code (ICD-9: 530.4, ICD-10: K22.3) within the year after the stricture code was calculated by year in both databases to assess this potential complication.
Direct annual medical costs associated with esophageal strictures in 2017 were calculated based on twelve age-sex strata. We used 2017 as this was the most recent year available for costs in both databases. We first calculated the sum of costs (in 2017 US dollars not accounting for current inflation) of all insurance claims (both inpatient and outpatient) in 2017 where esophageal strictures were listed as the first or second diagnosis code. Then, the calendar-year mean costs per period prevalent case were calculated by dividing the total costs by the total number of stricture cases in each stratum. Estimated esophageal stricture cases were calculated by multiplying the point prevalence of each age-sex stratum by the 2017 census population in each stratum.25 Total national annual medical costs associated with esophageal strictures in 2017 were estimated by multiplying the calendar-year mean costs per period prevalent case by the estimated total number of stricture cases in each age-sex stratum.
Results
Study Population
Overall, 25,871 patients met our primary esophageal stricture definition in the MarketScan database during 2021, 55% of whom were female, and the majority were aged 45 y and older (Table 1). In the Medicare cohort, 38,782 stricture patients were identified in 2017, 62% of whom were female, 91% were Non-Hispanic white/Caucasian, and most were aged 65–74 y.
Table 1.
Demographics of patients with esophageal strictures in MarketScan (2021) and Medicare (2017) with percentages among stricture patients.
| MarketScan (N=25871) | Medicare (N=38782) | ||||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Gender | |||||
| Male | 11703 | 45% | 14829 | 38% | |
| Female | 14168 | 55% | 23953 | 62% | |
| Race | |||||
| Non-Hispanic White/Caucasian | -- | -- | 35163 | 91% | |
| Black/African American | -- | -- | 2173 | 6% | |
| Asian/Pacific Islander | -- | -- | 245 | 1% | |
| Hispanic | -- | -- | 287 | 1% | |
| American Indian/Alaska Native | -- | -- | 121 | 0% | |
| Other | -- | -- | 358 | 1% | |
| Unknown | -- | -- | 435 | 1% | |
| Age | |||||
| <18 | 381 | 1% | |||
| 18–24 | 769 | 3% | |||
| 25–34 | 1700 | 7% | |||
| 35–44 | 3836 | 15% | |||
| 45–54 | 7990 | 31% | |||
| 55–64 | 11195 | 43% | |||
| 65–74 | 19588 | 51% | |||
| 75–84 | 14006 | 36% | |||
| 85+ | 5188 | 13% | |||
Prevalence
The prevalence of esophageal strictures (primary definition) in MarketScan in 2021 was 203.14 cases/100,000 people (95% CI: 200.67–205.61 cases/100,000 people). The annual prevalence was relatively stable with a gradual increase from 2000 to 2021 (Figure 1a) and was similar between male and female individuals (Figure 1b). As age increased, the esophageal strictures prevalence also increased, with 12.60 cases/100,000 people among individuals < 18 y and 524.92 cases/100,000 people among those 55–64 y in 2021 (Figure 1c). A similar prevalence trend across different age groups was also noted on sensitivity analysis (secondary definition) among patients who received esophageal dilation within one year before or after the stricture diagnosis (Figure 1d).
Figure 1.

Esophageal strictures prevalence among MarketScan patients between 2000 and 2021.
(A). Overall esophageal strictures prevalence among MarketScan patients between 2000 and 2021 using the primary case definition (one code). (B). Esophageal strictures prevalence by male and female sex. (C). Esophageal strictures prevalence across different age groups: less than 18 y, 18–24 y, 25–34 y, 35–44 y, 45–54 y, and 55–64 y. (D). Esophageal strictures prevalence using the secondary case definition (a dilation code within one-year before or after the stricture code) by age groups: less than 18 y, 18–24 y, 25–34 y, 35–44 y, 45–54 y, and 55–64 y.
The prevalence of esophageal strictures in Medicare in 2017 was 1123.47 cases/100,000 people (95% CI: 1112.35–1134.59 cases/100,000 people), which was the highest prevalence observed between 2007 and 2017 and reflected a gradual increase over that time (Figure 2a). The prevalence among females was somewhat higher than that among males (Figure 2b). Interestingly, the 75–84y age group had the highest prevalence among the three age groups (Figure 2c). The prevalence of esophageal strictures with esophageal dilation treatment was also similar among the three age groups in Medicare (Figure 2d).
Figure 2.

Esophageal strictures prevalence among Medicare patients between 2007 and 2017.
(A). Overall esophageal strictures prevalence among Medicare patients between 2007 and 2017 using the primary case definition (one code). (B). Esophageal strictures prevalence by male and female sex. (C). Esophageal strictures prevalence across different age groups: 65–74 y, 75–84 y, and 85 y and older. (D). Esophageal strictures prevalence using the secondary case definition (a dilation code within one-year before or after the stricture code) by age groups: 65–74 y, 75–84 y, and 85 y and older.
Diagnostic Codes Associated with Esophageal Strictures
The top diagnostic codes associated with esophageal stricture for both MarketScan and Medicare databases were GERD/erosive esophagitis. For MarketScan patients, 65.6% of esophageal stricture patients had a diagnostic code of GERD/erosive esophagitis within one year before/after the stricture diagnosis in 2001 and continued to increase to 81.1% in 2020 (Supplementary Figure 1a). For Medicare patients, the percentage of esophageal stricture patients with a diagnostic code of GERD/erosive esophagitis was consistently above 80% (Supplementary Figure 2a).
The “other esophagitis” category became increasingly prevalent in both MarketScan and Medicare over time (Supplementary Figure 1b and Supplementary Figure 2b). Interestingly, esophageal malignancies were among the top five diagnostic codes associated with strictures in MarketScan but not in Medicare. The proportion of stricture patients with an EoE diagnostic code within one year before or after the stricture diagnosis increased notably in MarketScan from 4.8% in 2009, the first full year an ICD code was available, to 16.4% in 2020 (Figure 3).
Figure 3.

The proportion of esophageal strictures patients with an eosinophilic esophagitis diagnostic code over the study time frame in Medicare and MarketScan databases.
Utilization and Costs
The utilization of endoscopies with dilation and endoscopies with biopsies in esophageal stricture patients was around 40–50% or higher in both Medicare and MarketScan cohorts (Table 2). The utilization of other stricture treatments, including endoscopy with injection, esophageal stenting, endoscopy with NG tube insertion, and others, was low in both cohorts. The proportion of stricture patients with an esophageal perforation code ranged from 0.1–0.4% each year in both cohorts (Supplementary Table 3).
Table 2.
Esophageal stricture treatment utilization proportions in MarketScan and Medicare databases.
| N (%) | Dataset | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| Period Prevalent Patients | Marketscan | 17722 | 18693 | 21591 | 26298 | 21012 | 22863 | 21821 | 23707 | 23902 | 22794 | 23670 | 22977 | 20041 |
| Medicare | 18712 | 19319 | 20204 | 21789 | 23066 | 26618 | 27868 | 30464 | 34511 | -- | -- | -- | -- | |
| Period Prevalent Patients with Dilation | Marketscan | 11055 | 14983 | 14762 | 18474 | 16913 | 17789 | 17508 | 20348 | 20645 | 18744 | 19390 | 19833 | 17138 |
| Medicare | 17724 | 18362 | 19139 | 20194 | 21492 | 22634 | 26082 | 28555 | 32528 | -- | -- | -- | -- | |
| Endoscopies with Dilation | Marketscan | 5883 (53.2) | 7938 (53.0) | 7868 (53.3) | 9687 (52.4) | 9070 (53.6) | 9491 (53.4) | 9141 (52.2) | 10542 (51.8) | 10594 (51.3) | 9637 (51.4) | 10035 (51.8) | 10229 (51.6) | 9154 (53.4) |
| Medicare | 8738 (49.3) | 9262 (50.4) | 9623 (50.3) | 10036 (49.7) | 10706 (49.8) | 11377 (50.3) | 13188 (50.6) | 14278 (50.0) | 16188 (49.8) | -- | -- | -- | -- | |
| Endoscopies without Dilation | Marketscan | 2155 (12.2) | 2072 (11.1) | 2420 (11.2) | 2936 (11.2) | 2223 (10.6) | 2269 (9.9) | 2041 (9.4) | 2253 (9.5) | 2109 (8.8) | 1832 (8.0) | 1803 (7.6) | 1685 (7.3) | 1295 (6.5) |
| Medicare | 3240 (17.3) | 3209 (16.6) | 3264 (16.2) | 3327 (15.3) | 3545 (15.4) | 3992 (15.0) | 3820 (13.7) | 4049 (13.3) | 4283 (12.4) | -- | -- | -- | -- | |
| Endoscopies with Biopsy | Marketscan | 9912 (55.9) | 10941 (58.5) | 12801 (59.3) | 15863 (60.3) | 12865 (61.2) | 14222 (62.2) | 13487 (61.8) | 14636 (61.7) | 14647 (61.3) | 14081 (61.8) | 14569 (61.6) | 14243 (62.0) | 12271 (61.2) |
| Medicare | 10202 (54.5) | 10736 (55.6) | 11445 (56.6) | 12406 (56.9) | 13174 (57.1) | 15326 (57.6) | 16094 (57.8) | 17510 (57.5) | 19794 (57.4) | -- | -- | -- | -- | |
| Endoscopies with NG tube Insertion | Marketscan | 15 (0.1) | 16 (0.1) | 29 (0.1) | 20 (0.1) | 22 (0.1) | 16 (0.1) | 24 (0.1) | 17 (0.1) | 23 (0.1) | 24 (0.1) | 28 (0.1) | 18 (0.1) | 27 (0.1) |
| Medicare | 21 (0.1) | 20 (0.1) | 18 (0) | 25 (0.1) | 36 (0.2) | 37 (0.1) | 39 (0.1) | 42 (0.1) | 53 (0.2) | -- | -- | -- | -- | |
| Endoscopies with PEG tube | Marketscan | 73 (0.4) | 70 (0.4) | 76 (0.4) | 92 (0.3) | 76 (0.4) | 73 (0.3) | 59 (0.3) | 59 (0.2) | 50 (0.2) | 53 (0.2) | 61 (0.3) | 56 (0.2) | 40 (0.2) |
| Medicare | 354 (1.9) | 320 (1.7) | 319 (1.6) | 328 (1.5) | 363 (1.6) | 410 (1.5) | 394 (1.4) | 408 (1.3) | 440 (1.3) | -- | -- | -- | -- | |
| Endoscopies with Injections | Marketscan | 110 (0.6) | 90 (0.5) | 135 (0.6) | 197 (0.7) | 154 (0.7) | 155 (0.7) | 154 (0.7) | 156 (0.7) | 131 (0.5) | 132 (0.6) | 154 (0.7) | 138 (0.6) | 130 (0.6) |
| Medicare | 227 (1.2) | 260 (1.3) | 251 (1.2) | 278 (1.3) | 328 (1.4) | 378 (1.4) | 411 (1.5) | 451 (1.5) | 469 (1.4) | -- | -- | -- | -- | |
| Esophageal stenting | Marketscan | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (0.1) | 40 (0.2) | 43 (0.2) | 41 (0.2) | 43 (0.2) | 49 (0.2) | 48 (0.2) | 40 (0.2) |
| Medicare | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 26 (0) | 87 (0.3) | 91 (0.3) | 105 (0.3) | -- | -- | -- | -- | |
| Endoscopies with Foreign Body Removal | Marketscan | 472 (2.7) | 563 (3.0) | 628 (2.9) | 844 (3.2) | 689 (3.3) | 734 (3.2) | 688 (3.2) | 781 (3.3) | 855 (3.6) | 788 (3.5) | 771 (3.3) | 826 (3.6) | 720 (3.6) |
| Medicare | 903 (4.8) | 937 (4.9) | 924 (4.6) | 955 (4.4) | 1008 (4.4) | 1180 (4.4) | 1226 (4.4) | 1272 (4.2) | 1474 (4.3) | -- | -- | -- | -- | |
Period prevalent patients with dilation required stricture patients with continuous enrollment for the entire year before and the entire year after the stricture diagnosis.
Esophageal stenting CPT code 43212 became available in 2014.38
The total healthcare costs associated with esophageal strictures were estimated to be $1,387,093,203.12 in 2017 (Table 3). The strata of men aged 45–64 y and women aged 45–64 y had the highest healthcare costs, estimated at $314,990,233.44 and $375,727,732.49, respectively. However, the highest total cost per case was among the men aged 25y or less and women aged 25y or less strata, estimated at $2827.83/case and $3582.35/case, respectively.
Table 3.
Total healthcare costs associated with esophageal strictures in 2017 in MarketScan and Medicare administrative databases.
| Sex | Age (y) | Mean total cost per case ($) | Total ($) |
|---|---|---|---|
|
| |||
| Men | <25 | 2,827.83 | 40,409,796.00 |
| Women | <25 | 3,582.35 | 30,791,408.65 |
| Men | 25–44 | 2,198.6 | 142,062,372.50 |
| Women | 25–44 | 2,100.59 | 115,528,769.32 |
| Men | 45–64 | 2,034.09 | 314,990,233.44 |
| Women | 45–64 | 1,917.26 | 375,727,732.49 |
| Men | 65–74 | 803.80 | 99,404,510.03 |
| Women | 65–74 | 484.07 | 80,986,825.28 |
| Men | 75–84 | 609.62 | 51,705,398.40 |
| Women | 75–84 | 554.57 | 63,222,302.74 |
| Men | 85+ | 1,187.85 | 38,692,684.98 |
| Women | 85+ | 735.01 | 33,571,169.30 |
| Total | 1,387,093,203.12 | ||
Discussion
Esophageal strictures are associated with serious adverse outcomes but their prevalence in the U.S. has not been well described. Using two large national insurance databases, we found that esophageal strictures are fairly common, with a prevalence of 203.14 cases/100,000 people in MarketScan in 2021 and a prevalence of 1123.47 cases/100,000 people in Medicare in 2017; prevalence increased with increasing age. Across data sources, GERD/erosive esophagitis-related codes were most commonly associated with strictures, esophageal malignancy was uncommon, and EoE increased notably to comprise a sizable proportion of stricture cases since 2009, especially in MarketScan. The healthcare impact of esophageal strictures was substantial, with estimated total healthcare costs up to $1.39 billion in 2017. For clinicians, it is important to know esophageal stricture prevalence as early recognition can help improve patient outcomes.
Previously, Nayyar and colleagues conducted a survey in the United Kingdom between 1977 and 1995 and found a stricture incidence of ~2%.26 However, its study population, patients with reflux disease in a single medical center, does not represent our intended study population, and their incidence cannot be directly compared to our prevalence findings. The only previous study similar to ours was by Ruigómez and colleagues, which estimated the esophageal stricture incidence in the UK between 1994 and 2000 was 1.1 per 10,000 person-years. This is also somewhat difficult to compare with our findings focusing on prevalence.17 Notably, these past two study populations were in Europe and may not apply to the U.S. population, or to the more current dates of our study. We are the first study to investigate esophageal strictures prevalence in the U.S. and to quantify financial and healthcare burden of the condition.
The top diagnostic codes associated with esophageal strictures were GERD/erosive esophagitis, which is not surprising given how frequently seen these conditions are.1,27,28 Interestingly, the proportion of esophageal stricture patients with an EoE diagnostic code within one year before/after the stricture diagnosis markedly increased over the past 15 years. We suspect this is due to a combination of the increasing incidence, prevalence, and recognition of EoE over this time frame.29,30
As would be expected, utilization of endoscopy, especially endoscopy with dilations and endoscopy with biopsies was high in patients with esophageal strictures. This is supported by current clinical guidelines for esophageal stricture treatment where endoscopy with dilation is the main treatment modality.1,31 In mild cases, where there are no symptoms or strictures are incidentally seen on endoscopy, no dilation would be needed.1,31 Since routine biopsies are often required to diagnose the underlying stricture etiology, their frequent use is appropriate.1,32 Esophageal stenting is reserved for refractory benign stricture and malignant stricture patients.1,33,34 Our findings are consistent with this assumption, as we found a very low proportion of esophageal stenting codes, suggesting that refractory strictures are uncommon.35 Despite variations in the types of procedures used, the high rate of endoscopy likely explains the approximately $1.39 billion total healthcare costs associated with esophageal strictures in 2017. This finding highlights the significant financial burden associated with esophageal strictures in the U.S. Specifically, this estimated total cost constitutes more than 6% of national healthcare expenditures associated with all esophageal disorders and is on par with the total costs associated with gastritis and duodenitis management combined.36 The estimated costs in 2017 dollars are likely an underestimate due to economic inflation.
Strengths of our study include the use of two large administrative databases providing an estimate of prevalence applicable to much of the U.S. population. Additionally, we were able to describe treatment utilization for specific procedures and estimate direct medical costs associated with these, which have not been previously characterized. Our study also has some limitations. Administrative claims data provide a limited amount of clinical information, such as endoscopy reports confirming the stricture diagnosis or pathology reports, which makes it challenging to directly assess the etiology of esophageal strictures. Our primary stricture case definition has not been previously validated; thus the sensitivity and specificity of our definition are unknown. To address this, we defined a secondary definition of a strictures case, which required both a stricture code and a dilation code. We feel it would be unlikely that a patient would have both codes and not truly have a stricture, so these prevalence estimates should provide a lower limit. It is also possible, however, that our calculated prevalence could underestimate the true national prevalence because uninsured and Medicaid patients were not included in the study and this population has been found to have a higher endoscopy no-show rate.37 Another limitation is that our databases do not capture the time-trend of GERD-related strictures pre- and post-PPI approvals since most PPIs were approved predating 2002. Lastly, administrative databases do not fully capture data related to known risk factors associated with strictures, such as race (not reported in MarketScan), alcohol use, smoking habits, and others.
In conclusion, esophageal strictures in the United States are common, with prevalence ranging from 1/1000 to higher than 1/100 as age increases, especially among adults above 65y. Esophageal stricture codes are most associated with GERD/erosive esophagitis, but EoE diagnoses are an increasingly more prevalent cause of strictures among younger patients based on MarketScan data. Additionally, esophageal stricture poses a significant financial burden on the U.S. healthcare system, with more than $1 billion in healthcare costs annually. Understanding the prevalence, particularly among older age groups, can inform practice and guidelines aimed at linking patients with symptoms to earlier diagnosis and treatment.
Supplementary Material
What you need to know:
BACKGROUND AND CONTEXT:
Data on the prevalence, disease burden, and healthcare utilization of esophageal stricture in the U.S. are lacking.
NEW FINDINGS:
This retrospective cohort study utilizing two administrative claims databases found esophageal stricture is common in the US and is associated with high financial burden and healthcare utilization.
LIMITATIONS:
Limited clinical information is provided in administrative databases.
CLINICAL RESEARCH RELEVANCE:
Esophageal stricture prevalence increases with increasing age. Providers should have high levels of suspicion for esophageal strictures in the appropriate clinical, and understand their substantial burden of disease.
Funding Source:
This study was supported by NIH T35 DK007386, T32 DK007634, and used resources from the UNC Center for GI Biology and Disease (P30 DK034987).
Footnotes
Conflict of Interest: None of the authors report any potential conflicts of interest with this study.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Data Transparency Statement:
Data, analytic methods, and study materials may be made available to other researchers for reasonable requests and if permissions are in place.
References
- 1.Desai JP, & Moustarah F (2022). Esophageal Stricture. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK542209/ [PubMed] [Google Scholar]
- 2.Ferguson DD (2005). Evaluation and management of benign esophageal strictures. Diseases of the Esophagus, 18(6), 359–364. 10.1111/j.1442-2050.2005.00516.x [DOI] [PubMed] [Google Scholar]
- 3.Smith CD (2015). Esophageal Strictures and Diverticula. Surgical Clinics of North America, 95(3), 669–681. 10.1016/j.suc.2015.02.017 [DOI] [PubMed] [Google Scholar]
- 4.Hwang JJ (2017). Safe and Proper Management of Esophageal Stricture Using Endoscopic Esophageal Dilation. Clinical Endoscopy, 50(4), 309. 10.5946/ce.2017.100 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ramage JIJ, Rumalla A, Baron TH, et al. (2005). A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Endoscopic Steroid Injection Therapy for Recalcitrant Esophageal Peptic Strictures. Official Journal of the American College of Gastroenterology | ACG, 100(11), 2419. https://journals.lww.com/ajg/Fulltext/2005/11000/A_Prospective,_Randomized,_Double_Blind,.11.aspx [DOI] [PubMed] [Google Scholar]
- 6.Spechler SJ (1999). AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology, 117(1), 233–254. 10.1016/s0016-5085(99)70573-1 [DOI] [PubMed] [Google Scholar]
- 7.Marks RD, & Richter JE (1993). Peptic strictures of the esophagus. The American Journal of Gastroenterology, 88(8), 1160–1173. [PubMed] [Google Scholar]
- 8.Pech O, May A, Manner H, et al. (2014). Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology, 146(3), 652–660.e1. 10.1053/j.gastro.2013.11.006 [DOI] [PubMed] [Google Scholar]
- 9.Pierie JP, de Graaf PW, Poen H, et al. (1993). Incidence and management of benign anastomotic stricture after cervical oesophagogastrostomy. The British Journal of Surgery, 80(4), 471–474. 10.1002/bjs.1800800422 [DOI] [PubMed] [Google Scholar]
- 10.Boyce HW (2005). Dilation of Difficult Benign Esophageal Strictures. Official Journal of the American College of Gastroenterology | ACG, 100(4), 744. https://journals.lww.com/ajg/Fulltext/2005/04000/Dilation_of_Difficult_Benign_Esophageal_Strictures.3.aspx [DOI] [PubMed] [Google Scholar]
- 11.Beg MH, & Reyazuddin. (1988). Distal esophageal stricture due to indwelling nasogastric tube. The Indian Journal of Chest Diseases & Allied Sciences, 30(1), 64–66. [PubMed] [Google Scholar]
- 12.Agha FP (1984). Candidiasis-induced esophageal strictures. Gastrointestinal Radiology, 9(4), 283–286. 10.1007/BF01887852 [DOI] [PubMed] [Google Scholar]
- 13.Perry Y, Epperly MW, Fernando HC, et al. (2005). Photodynamic therapy induced esophageal stricture--an animal model: From mouse to pig. The Journal of Surgical Research, 123(1), 67–74. 10.1016/j.jss.2004.05.006 [DOI] [PubMed] [Google Scholar]
- 14.Gurala D, Polavarapu A, Philipose J, et al. (2021). Esophageal Food Impaction: A Retrospective Chart Review. Gastroenterology Research, 14(3), 173–178. 10.14740/gr1387 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Vermeulen BD, de Zwart M, Sijben J, et al. (2020). Risk factors and clinical outcomes of endoscopic dilation in benign esophageal strictures: A long-term follow-up study. Gastrointestinal Endoscopy, 91(5), 1058–1066. 10.1016/j.gie.2019.12.040 [DOI] [PubMed] [Google Scholar]
- 16.Patterson DJ, Graham DY, Smith JL, et al. (1983). Natural history of benign esophageal stricture treated by dilatation. Gastroenterology, 85(2), 346–350. [PubMed] [Google Scholar]
- 17.Ruigómez A, Alberto García Rodríguez L, Wallander M-A, et al. (2006). Esophageal Stricture: Incidence, Treatment Patterns, and Recurrence Rate. Official Journal of the American College of Gastroenterology | ACG, 101(12), 2685. https://journals.lww.com/ajg/Fulltext/2006/12000/Esophageal_Stricture__Incidence,_Treatment.5.aspx [DOI] [PubMed] [Google Scholar]
- 18.Merative Marketscan Research Databases. (n.d.). Retrieved September 3, 2023, from https://www.merative.com/documents/brief/marketscan-explainer-general
- 19.Division (DCD), D. C. (12 C.E., February 9). Who’s eligible for Medicare? [Text]. HHS.Gov. https://www.hhs.gov/answers/medicare-and-medicaid/who-is-eligible-for-medicare/index.html [Google Scholar]
- 20.Medicare Administrative Data—Healthy People 2030 | health.gov. (n.d.). Retrieved July 14, 2023, from https://health.gov/healthypeople/objectives-and-data/data-sources-and-methods/data-sources/medicare-administrative-data
- 21.SAS 9.4 Software Overview for the Customer. (n.d.). Retrieved June 24, 2023, from https://support.sas.com/software/94/
- 22.Rassen JA, Bartels DB, Schneeweiss S, et al. (2018). Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clinical Epidemiology, 11, 1–15. 10.2147/CLEP.S181242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Gaber CE, Eluri S, Cotton CC, et al. (2022). Epidemiologic and Economic Burden of Achalasia in the United States. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 20(2), 342–352.e5. 10.1016/j.cgh.2021.02.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Jensen ET, Cook SF, Allen JK, et al. (2015). Enrollment factors and bias of disease prevalence estimates in administrative claims data. Annals of Epidemiology, 25(7), 519–525.e2. 10.1016/j.annepidem.2015.03.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Bureau UC (n.d.). Age and Sex Composition in the United States: 2017. Census.Gov. Retrieved June 19, 2023, from https://www.census.gov/data/tables/2017/demo/age-and-sex/2017-age-sex-composition.html [Google Scholar]
- 26.Nayyar AK, Royston C, & Bardhan KD (2003). Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era. Digestive and Liver Disease, 35(3), 143–150. 10.1016/S1590-8658(03)00021-5 [DOI] [PubMed] [Google Scholar]
- 27.Kuo WH, & Kalloo AN (1998). Reflux strictures of the esophagus. Gastrointestinal Endoscopy Clinics of North America, 8(2), 273–281. [PubMed] [Google Scholar]
- 28.Schlachta CM, Poulin EC, Mamazza J, et al. (2001). Peptic strictures of the esophagus. In Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt. https://www.ncbi.nlm.nih.gov/books/NBK6899/ [Google Scholar]
- 29.Dellon ES & Hirano I (2018). Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology, 154(2), 319–332.e3. 10.1053/j.gastro.2017.06.067 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Arias Á, Pérez-Martínez I, Tenías JM, et al. (2016). Systematic review with meta-analysis: The incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Alimentary Pharmacology & Therapeutics, 43(1), 3–15. 10.1111/apt.13441 [DOI] [PubMed] [Google Scholar]
- 31.Standards of Practice Committee, Egan JV, Baron TH, et al. (2006). Esophageal dilation. Gastrointestinal Endoscopy, 63(6), 755–760. 10.1016/j.gie.2006.02.031 [DOI] [PubMed] [Google Scholar]
- 32.Muir AB, Merves J, & Liacouras CA (2016). Role of Endoscopy in Diagnosis and Management of Pediatric Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America, 26(1), 187. 10.1016/j.giec.2015.08.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hindy P, Hong J, Lam-Tsai, et al. (2012). A Comprehensive Review of Esophageal Stents. Gastroenterology & Hepatology, 8(8), 526. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533211/ [PMC free article] [PubMed] [Google Scholar]
- 34.Sharma P & Kozarek R (2010). Role of esophageal stents in benign and malignant diseases. The American Journal of Gastroenterology, 105(2). 10.1038/ajg.2009.684 [DOI] [PubMed] [Google Scholar]
- 35.Salo JA & Sihvo EIT (2001). Instrumental perforation of the esophagus. In Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt. https://www-ncbi-nlm-nih-gov.libproxy.lib.unc.edu/books/NBK6892/ [PubMed] [Google Scholar]
- 36.Peery AF, Crockett SD, Murphy CC, et al. (2022). Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology, 162(2), 621–644. 10.1053/j.gastro.2021.10.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Garrison K, Gaglani T, Chase M, et al. (2022). S1513 Insurance Status Predicts Endoscopy No-Show. Official Journal of the American College of Gastroenterology | ACG, 117(10S), e1084. 10.14309/01.ajg.0000862692.20884.db [DOI] [Google Scholar]
- 38.2014 CPT Coding Updates. (n.d.). Retrieved August 18, 2023, from https://www.asge.org/docs/default-source/practice-support/coding/074a7ebc-2222-4d00-94eb-701d6a8e0ec6.pdf
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data, analytic methods, and study materials may be made available to other researchers for reasonable requests and if permissions are in place.
